BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 28454892)

  • 1. DNA damage response activation and cell cycle dysregulation in infiltrative ameloblastomas: A proposed model for ameloblastoma tumor evolution.
    Diniz MG; Guimarães BVA; Pereira NB; de Menezes GHF; Gomes CC; Gomez RS
    Exp Mol Pathol; 2017 Jun; 102(3):391-395. PubMed ID: 28454892
    [No Abstract]   [Full Text] [Related]  

  • 2. BRAFV600E mutation in the diagnosis of unicystic ameloblastoma.
    Pereira NB; Pereira KM; Coura BP; Diniz MG; de Castro WH; Gomes CC; Gomez RS
    J Oral Pathol Med; 2016 Nov; 45(10):780-785. PubMed ID: 27084044
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High frequency of BRAF V600E mutations in ameloblastoma.
    Kurppa KJ; Catón J; Morgan PR; Ristimäki A; Ruhin B; Kellokoski J; Elenius K; Heikinheimo K
    J Pathol; 2014 Apr; 232(5):492-8. PubMed ID: 24374844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. p53 gene status and expression of p53, MDM2, and p14 proteins in ameloblastomas.
    Kumamoto H; Izutsu T; Ohki K; Takahashi N; Ooya K
    J Oral Pathol Med; 2004 May; 33(5):292-9. PubMed ID: 15078490
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of BRAFV600E and SMOF412E mutations in epithelial odontogenic tumours.
    Diniz MG; Gomes CC; Guimarães BV; Castro WH; Lacerda JC; Cardoso SV; de Faria PR; Dias FL; Eisenberg AL; Loyola AM; Gomez RS
    Tumour Biol; 2015 Jul; 36(7):5649-53. PubMed ID: 25854168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activating FGFR2-RAS-BRAF mutations in ameloblastoma.
    Brown NA; Rolland D; McHugh JB; Weigelin HC; Zhao L; Lim MS; Elenitoba-Johnson KS; Betz BL
    Clin Cancer Res; 2014 Nov; 20(21):5517-26. PubMed ID: 24993163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upregulation of Periostin expression in the pathogenesis of ameloblastoma.
    Kang Y; Liu J; Zhang Y; Sun Y; Wang J; Huang B; Zhong M
    Pathol Res Pract; 2018 Dec; 214(12):1959-1965. PubMed ID: 30196986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression of parathyroid hormone-related protein in ameloblastomas.
    Ohtsuru M
    Tokai J Exp Clin Med; 2005 Dec; 30(4):233-9. PubMed ID: 16482944
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress towards personalized medicine for ameloblastoma.
    Gomes CC; Diniz MG; Gomez RS
    J Pathol; 2014 Apr; 232(5):488-91. PubMed ID: 24749150
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Allelic loss of the ING gene family loci is a frequent event in ameloblastoma.
    Borkosky SS; Gunduz M; Beder L; Tsujigiwa H; Tamamura R; Gunduz E; Katase N; Rodriguez AP; Sasaki A; Nagai N; Nagatsuka H
    Oncol Res; 2010; 18(10):509-18. PubMed ID: 20681410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression of proteoglycans in two types of ameloblastoma: novel Immunohistochemical findings.
    Gómez-Herrera Z; Molina-Frechero N; Damián-Matsumura P; González-González R; Farfán-Morales JE; Bologna-Molina R
    J Biol Regul Homeost Agents; 2018; 32(3):479-487. PubMed ID: 29921372
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Overexpression of MDM2 protein in ameloblastomas as compared to adenomatoid odontogenic tumor.
    Krishna A; Kaveri H; Naveen Kumar RK; Kumaraswamy KL; Shylaja S; Murthy S
    J Cancer Res Ther; 2012; 8(2):232-7. PubMed ID: 22842367
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Correlations of extrocellular matrix metalloproteinase inducer and microvessel density to invasiveness of ameloblastoma].
    Jiang LJ; Shao CK; He D; Li WG; Wu XZ; Cai DZ
    Ai Zheng; 2008 Dec; 27(12):1263-6. PubMed ID: 19079990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ameloblastoma with mucous cells: A clinicopathological, BRAF mutation, and MAML2 rearrangement study.
    Xia RH; Zhang CY; Sun JJ; Tian Z; Hu YH; Gu T; Wang LZ; Li J
    Oral Dis; 2020 May; 26(4):805-814. PubMed ID: 31954088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. K-Ras gene status and expression of Ras/mitogen-activated protein kinase (MAPK) signaling molecules in ameloblastomas.
    Kumamoto H; Takahashi N; Ooya K
    J Oral Pathol Med; 2004 Jul; 33(6):360-7. PubMed ID: 15200485
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of heterozygosity of the PTCH gene in ameloblastoma.
    Farias LC; Gomes CC; Brito JA; Galvão CF; Diniz MG; de Castro WH; Bernardes Vde F; De Marco LA; Gomez RS
    Hum Pathol; 2012 Aug; 43(8):1229-33. PubMed ID: 22221699
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of novel molecular characteristics and cellular biological properties in ameloblastoma.
    Kondo S; Ota A; Ono T; Karnan S; Wahiduzzaman M; Hyodo T; Lutfur Rahman M; Ito K; Furuhashi A; Hayashi T; Konishi H; Tsuzuki S; Hosokawa Y; Kazaoka Y
    Cancer Med; 2020 Apr; 9(8):2904-2917. PubMed ID: 32096304
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of recurrent SMO and BRAF mutations in ameloblastomas.
    Sweeney RT; McClary AC; Myers BR; Biscocho J; Neahring L; Kwei KA; Qu K; Gong X; Ng T; Jones CD; Varma S; Odegaard JI; Sugiyama T; Koyota S; Rubin BP; Troxell ML; Pelham RJ; Zehnder JL; Beachy PA; Pollack JR; West RB
    Nat Genet; 2014 Jul; 46(7):722-5. PubMed ID: 24859340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Research advances in the v-raf murine sarcoma viral oncogene homolog gene mutation in ameloblastoma].
    Yan XC; Sun LS; Dong ZW; You Z; Dong Q
    Zhonghua Kou Qiang Yi Xue Za Zhi; 2018 Jul; 53(7):500-502. PubMed ID: 29996373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ameloblastoma-Clinical, radiological, and therapeutic findings.
    Kreppel M; Zöller J
    Oral Dis; 2018 Mar; 24(1-2):63-66. PubMed ID: 29480593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.